Why Durable Medical Equipment Providers Are Losing Revenue Before the Claim Is Even Submitted

Most conversations about Durable Medical Equipment reimbursement start in the billing department. That is roughly three weeks too late. By the time a DME claim reaches a biller, the outcome is usually decided. Paperwork nobody in billing ever touched settled it.

The numbers make this uncomfortable rather than theoretical. CMS reports that DMEPOS carried $1.9 billion in improper payments during fiscal year 2024, a rate of 21.4%. The FY2025 figure came in higher still at 24.12%, the worst of any Medicare fee-for-service claim type. The national rate across all Medicare claims was 6.55% for the same period.

So DME suppliers lose money at nearly four times the Medicare average. More importantly, CMS is explicit about why. Reviewing continuous glucose monitors, the agency found the majority of errors related to missing or insufficient documentation. Not fraud. Not coding. Paperwork that was incomplete before anyone submitted anything.

This guide covers where DME reimbursement actually breaks, and the two 2026 rule changes reshaping it. It also covers what functioning intake looks like operationally.

Why DMEPOS Loses More Than Any Other Claim Type

Every other Medicare provider bills for something they did. A DME supplier bills for something delivered on someone else’s authority. The order came from a practitioner, after an encounter the supplier never attended.

That structure creates a dependency chain no other claim type carries. The treating practitioner must see the patient. They must document that encounter properly in their record, not yours. The practitioner must then create and sign a Standard Written Order. Only then can the item ship.

Break any link and the claim fails, regardless of how clean your claims processing is. Worse, you frequently cannot see the break until a denial arrives weeks later. Consequently, the DME revenue cycle is less a billing function than a documentation supply chain.

The category-level data shows how badly this scales. CMS found FY2024 improper payment rates for orthotic braces ranging between 35.2% and 54.4%. Continuous glucose monitors sat at 25.2%. They produced the highest projected improper payments of any DMEPOS item, around $278 million.

The Five Points Where DME Reimbursement Actually Breaks

Each of these sits upstream of claim submission. Each one is fixable with process rather than technology.

The face-to-face encounter. For items on the Required List, a compliant face-to-face encounter must occur before the order. The note lives in the practitioner’s chart rather than yours. You are auditing a document you do not control. Suppliers who check this at billing discover the gap after delivery. By then the equipment sits in a patient’s home.

Meanwhile the sequencing trips people constantly. The encounter must precede the Standard Written Order. The written order prior to delivery must then be completed within six months. Getting both documents but in the wrong order still produces a denial.

The Standard Written Order. Since January 2020, an SWO must be in the supplier’s possession before billing any DMEPOS item. Missing or incomplete SWOs are the single most common reason for DMEPOS claim denials in CERT data. The required elements are unforgiving. They include beneficiary name or MBI, item description, practitioner name and NPI, order date, and a compliant signature.

Two details catch suppliers repeatedly. CMS does not permit signature or date stamps. Also, a prescription alone does not count as medical record. Clinical information on it must be corroborated elsewhere in the chart.

Eligibility and benefit verification. Coverage at intake and coverage on the date of service differ. Our eligibility verification checklist covers the full sequence. Plan terminations, Medicare Advantage enrollment changes, and secondary payer shifts all move between order and delivery. This is straightforward to prevent and expensive to discover late, which is why disciplined insurance verification workflows pay for themselves quickly in DME.

Prior authorization. Certain DMEPOS HCPCS codes require prior authorization ahead of delivery. A provisional affirmation is not a payment guarantee. However, a non-affirmation before delivery is a denial you can still prevent. Delivering ahead of the decision converts a solvable problem into written-off revenue.

Proof of delivery. The last mile is now a documented enforcement priority. The CERT Task Force reported a significant increase in Proof of Delivery denials from the DME MACs. Every other document can be perfect, and an incomplete delivery receipt still sinks the claim.

What Changed in April 2026: 83 New Codes on the Required List

Here is the development most DME suppliers underestimated. CMS published CMS-6097-N in the Federal Register on January 13, 2026. It expanded the DMEPOS Required List by 83 HCPCS codes, effective April 13, 2026.

The Required List is the subset where face-to-face and written order requirements are actively enforced. They function as conditions of payment. Adding 83 codes therefore adds 83 new ways to be denied. Each requires a documented encounter preceding a signed order.

Suppliers who processed those codes routinely for years now handle them under stricter conditions. Notably, the risk concentrates among high-volume items where staff has built habits around a simpler workflow. Habit is the enemy here, because nothing about the order looks different at intake.

The practical control is unglamorous. Your workflow needs a hard check comparing encounter date against SWO date. Run it before delivery rather than after a denial. Whether that runs as a checklist or a system rule matters far less than whether it runs at all.

The 2026 Rule Almost Nobody Is Talking About

Now the part that should genuinely change how DME leaders think about documentation. On December 2, 2025, CMS issued CMS-1828-F, establishing a prior authorization exemption process for certain DMEPOS items.

Read the mechanism carefully. Suppliers demonstrating billing compliance with Medicare coverage, coding, and payment requirements can exit required prior authorization. The qualifying threshold is a provisional affirmation rate of 90% or higher. Suppliers may also opt out of the exemption if they prefer.

That inverts the entire industry framing of documentation. For twenty years, DME suppliers have treated compliance as a cost of doing business. It was a revenue tax, minimized where possible.

CMS just turned it into a competitive advantage. A supplier holding 90% provisional affirmation exits prior authorization on eligible items. That means faster patient delivery and shorter cash conversion cycles. Administrative load drops below competitors still awaiting authorization decisions.

Consider what that does to a referral relationship. Two suppliers quote the same equipment to the same discharge planner. One delivers within days. The other needs a prior authorization decision first. The documentation quality that felt like overhead just became the reason one of them wins the account.

Therefore, the strategic question has changed. It is no longer how little documentation work you can get away with. It is whether you can reach 90% and stay there.

What Good DME Intake Actually Looks Like

Four disciplines separate suppliers who hold high affirmation rates from those who do not.

Verify before you deliver, not before you bill. Confirm eligibility, prior authorization, encounter documentation, and SWO completeness first. Do it while the item still sits in your warehouse. Once equipment reaches a patient’s home, every problem becomes materially more expensive.

Chase the encounter note actively rather than assuming it exists. The face-to-face documentation sits in a practitioner’s chart, and practitioners are not thinking about your Required List. Someone has to request it, review it against the SWO date, and follow up when it is inadequate.

Track affirmation rate as an operational metric, not a compliance report. Under the exemption rule, that number now carries direct commercial value. Most suppliers currently review it quarterly at best, which is far too slow to manage toward a 90% threshold.

Finally, respond to audit requests inside the window. Answer CERT documentation requests within 75 days. Miss that window and the claim lands in the “No Documentation” category. That category is the most avoidable denial in the DME revenue cycle. It is purely an administrative failure.

Real programs demonstrate the upside. One home medical equipment supplier integrated dedicated verification support into its existing platform. Eligibility denials fell from 14% to under 4% within 60 days, and order-to-delivery time shortened by 30%. Our breakdown of DME insurance verification outsourcing covers how that was structured.

The Economics of Fixing DME Documentation Upstream

Every denied DME claim carries costs that never appear on a denial report. You already delivered the equipment, so you hold the asset cost. Staff burn hours preparing the appeal. Cash conversion stretches while the balance ages.

Compare that against the cost of preventing it. Verification, prior authorization follow-up, and documentation chasing are all non-clinical administrative work. They require diligence and payer knowledge rather than clinical licensure. That makes them well suited to dedicated specialist teams.

The constraint is usually capacity rather than willingness. Most DME suppliers run lean administrative teams already stretched across intake, billing, and patient communication. A rigorous pre-delivery verification step means adding hours nobody currently has. That is why revenue cycle support capacity increasingly sits alongside internal teams.

The arithmetic favors prevention heavily. A denial costs the equipment, the appeal labor, and the delay. Verification costs minutes. Against a 24% improper payment rate, that trade is not close.